DCTI is a research initiative to improve beta-cell replacement therapy and to make this therapy accessible for more patients with diabetes. The main research goals are to increase the availability of high quality insulin-producing cells and the development of alternative transplantation sites and to identify factors for long-term islet function and survival with the use of biomaterials.
Five research areas contribute to this goal:
Schematic overview of overarching goal with time line and research areas
Several DCTI partners have joined RegMed XB (www.regmedxb.com) to build on the knowledge generated within DCTI.
Eelco de Koning (Scientific Director)
e.dekoning[at]lumc[dot]nl
071-5262085
Margot Beukers (Managing Director)
dcti[at]sbsupport[dot]nl
071-5324733